← All trials
NCT00245336
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2005
- Primary completion
- Jun 1, 2006
- Completion date
- Jul 1, 2006
- First posted
- —
- Last posted
- —
- Enrollment
- 401
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- ZymoGeneticsLead sponsor
- University of Southern CaliforniaOverall official - principal investigator
- Indiana Spine GroupOverall official - principal investigator
- ZymoGeneticsStudy director
- Washington University in St. LouisOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.